Methods of administering elagolix
US11690845B2 · kind B2 · utility
0Cited by
6References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 27, 2020 |
| Grant date | Jul 4, 2023 |
| Priority date | — |
| Expiry date | Aug 27, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/57
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.